Table 2 Efficay and alterations in EGFR mutations of afatinib treatment.
Patient | EGFR mutations in ctDNA before Afatinib | Response to Afatinib | PFS (months) | EGFR mutations in ctDNA progression after Afatinib |
|---|---|---|---|---|
KU-01 | E746-A750 del, T790M | SD | 1.8 | E746-A750 del, T790M, C797S |
KU-02 | E746-A750 del, T790M | SD | 3.4 | E746-A750 del, T790M, C797S |
KU-03 | L858R | SD | 2.5 | L858R, T790M |
KU-04 | L858R | SD | 1.5 | L858R |
KU-05 | L858R | PD | 0.9 | L858R |
KU-06 | L858R, T790M | PD | 0.9 | L858R, T790M |
KU-07 | T790M, C797S | PD | 0.9 | T790M, C797S |
KU-08 | absent | PD | 2.2 | absent |
KU-09 | L858R | PD | 2.0 | L858R |
